Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: A surveillance project

Blood

Volumn 129, Issue 17, 2017, Pages 2368-2374

  Manco Johnson, Marilyn J ^a   Soucie, J Michael ^b   Gill, Joan Cox ^c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIC ARTHROPATHY; HUMAN; JOINT FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANGE OF MOTION; STATISTICAL ANALYSIS; TREND STUDY; UNITED STATES; AGE; AMBULATORY CARE; DRUG EFFECTS; HEMORRHAGE; JOINT; JOINT CHARACTERISTICS AND FUNCTIONS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIMARY PREVENTION; PROSPECTIVE STUDY; REGISTER; STATISTICS AND NUMERICAL DATA; VASCULARIZATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; JOINTS; MALE; MIDDLE AGED; OFFICE VISITS; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; REGISTRIES; UNITED STATES;

EID: 85018046272     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-683169     Document Type: Article

References (18)

1. Valentino LA. Blood-induced joint disease: The pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8(9):1895-1902.
2. Aledort LM, Haschmeyer RH, Pettersson H; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor- VIII-deficient haemophiliacs. J Intern Med. 1994; 236(4):391-399.
3. Iannone M, Pennick L, Tom A, et al. Prevalence of depression in adults with haemophilia. Haemophilia. 2012;18(6):868-874.
4. Cassis FRMY, Querol F, Forsyth A, Iorio A; HERO International Advisory Board. Psychosocial aspects of haemophilia: A systematic review of methodologies and findings. Haemophilia. 2012;18(3):e101-e114.
5. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
6. Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11(6):1119-1127.
7. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol. 1994;47(2):113-117.
8. Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med. 2011;41(6 suppl 4): S360-S368.
9. Bladen M, Main E, Hubert N, Koutoumanou E, Liesner R, Khair K. Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia. Haemophilia. 2013;19(4): 626-631.
10. Soucie JM, Wang C, Siddiqi A, Kulkarni R, Recht M, Konkle BA; Hemophilia Treatment Center Network. The longitudinal effect of body adiposity on joint mobility in young males with haemophilia A. Haemophilia. 2011;17(2):196-203.
11. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med. 2010;38(suppl 4):S475-S481.
12. Soucie JM, Wang C, Forsyth A, et al; Hemophilia Treatment Center Network. Range of motion measurements: Reference values and a database for comparison studies. Haemophilia. 2011;17(3): 500-507.
13. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25-32.
14. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?-The German experience. Haemophilia. 1998;4(4):413-417.
15. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002;99(7):2337-2341.
16. Lundin B, Hong W, Raunig D, et al. Effect on joint health of routine prophylaxis with Bayer's sucrose-formulated recombinant factor VIII (rFVIII-FS) in adolescents and adults previously treated on demand: MRI analyses from the 3-year Spinart study [abstract]. Blood. 2014;124(21). Abstract 2854.
17. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: Results from a 13-month crossover study. J Thromb Haemost. 2010;8(1): 83-89.
18. Valentino LA, Mamonov V, Hellmann A, et al; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367.